PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31934166-7 2019 ERalpha36-EGFR-Her-2 feedback loop, PI3K/Akt and MAPK/ERK pathways were inhibited, while caspase 3 was activated by EGCG in Hep3B cells, with p-ERK accumulated in cytoplasm. epigallocatechin gallate 116-120 erb-b2 receptor tyrosine kinase 2 Homo sapiens 15-20 34940773-0 2022 Multi-ligand modified PC@DOX-PA/EGCG micelles effectively inhibit the growth of ER+, PR+ or HER2+ breast cancer. epigallocatechin gallate 32-36 erb-b2 receptor tyrosine kinase 2 Homo sapiens 92-96 31934166-9 2019 This is the first evidence that EGCG exerts its anti-cancer effect by inhibiting ERalpha36, followed with inhibition of the ERalpha36-EGFR-Her-2 feedback loop and PI3K/Akt, MAPK/ERK pathway, activation of caspase 3, and accumulation of p-ERK in cytoplasm. epigallocatechin gallate 32-36 erb-b2 receptor tyrosine kinase 2 Homo sapiens 139-144 30207689-4 2018 The outmost HER2 aptamer (HB5) governs the recognition to HER2 protein overexpressed in SK-BR-3 cell lines, while the ATP aptamer incorporated with anticancer drug (-)-epigallocatechin gallate (EGCG) and protamine sulfate in the inner core functions as a switch of drug release in response to abundant intracellular ATP. epigallocatechin gallate 164-192 erb-b2 receptor tyrosine kinase 2 Homo sapiens 12-16 30207689-4 2018 The outmost HER2 aptamer (HB5) governs the recognition to HER2 protein overexpressed in SK-BR-3 cell lines, while the ATP aptamer incorporated with anticancer drug (-)-epigallocatechin gallate (EGCG) and protamine sulfate in the inner core functions as a switch of drug release in response to abundant intracellular ATP. epigallocatechin gallate 164-192 erb-b2 receptor tyrosine kinase 2 Homo sapiens 58-62 30207689-4 2018 The outmost HER2 aptamer (HB5) governs the recognition to HER2 protein overexpressed in SK-BR-3 cell lines, while the ATP aptamer incorporated with anticancer drug (-)-epigallocatechin gallate (EGCG) and protamine sulfate in the inner core functions as a switch of drug release in response to abundant intracellular ATP. epigallocatechin gallate 194-198 erb-b2 receptor tyrosine kinase 2 Homo sapiens 12-16 30207689-4 2018 The outmost HER2 aptamer (HB5) governs the recognition to HER2 protein overexpressed in SK-BR-3 cell lines, while the ATP aptamer incorporated with anticancer drug (-)-epigallocatechin gallate (EGCG) and protamine sulfate in the inner core functions as a switch of drug release in response to abundant intracellular ATP. epigallocatechin gallate 194-198 erb-b2 receptor tyrosine kinase 2 Homo sapiens 58-62 17909003-0 2007 Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. epigallocatechin gallate 71-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 22-26 29329808-4 2018 Herein we combined structural data and molecular dynamics (MD) simulations coupled to an MMGBSA approach to provide insight into the binding mechanism between two dual synthetics (lapatinib and TAK-285) and one dual natural inhibitor (EGCG) which target EGFR/HER2. epigallocatechin gallate 235-239 erb-b2 receptor tyrosine kinase 2 Homo sapiens 259-263 28462491-7 2017 Our studies demonstrate that combination of Erlotinib and EGCG with MTX and ACD decreases JAR cell proliferation and metastatic HER2 protein synthesis and increases caspase-3 activation compared to ACD or MTX alone. epigallocatechin gallate 58-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 128-132 19113837-11 2009 In EGCG-treated human ovarian carcinoma SKOV3 cells, decreased levels of several cancer-related hsp90 client proteins, such as ErbB2, Raf-1 and phospho-AKT, were observed. epigallocatechin gallate 3-7 erb-b2 receptor tyrosine kinase 2 Homo sapiens 127-132 18618485-0 2008 Comparison of delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation. epigallocatechin gallate 41-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 106-111 18618485-3 2008 In addition, delphinidin, quercetin and (-)-epigallocatechin-3-gallate (EGCG) were found to suppress the phosphorylation of the ErbB2 receptor, with delphinidin exhibiting the strongest inhibitory properties. epigallocatechin gallate 40-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 128-133 18618485-3 2008 In addition, delphinidin, quercetin and (-)-epigallocatechin-3-gallate (EGCG) were found to suppress the phosphorylation of the ErbB2 receptor, with delphinidin exhibiting the strongest inhibitory properties. epigallocatechin gallate 72-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 128-133 18618485-4 2008 Their potency to suppress the ErbB2 receptor phosphorylation can be summarised as delphinidin > EGCG > quercetin. epigallocatechin gallate 99-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 30-35 17902053-7 2008 Treating cancer cells with EGCG or C75 induced apoptosis and caused a decrease in the active forms of oncoprotein HER2, AKT and ERK1/2 to a similar degree. epigallocatechin gallate 27-31 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-118 26107737-4 2015 The cellular interactions of combining anti-FASN polyphenolic compounds (EGCG and the synthetic G28UCM) with anti-HER2 signaling drugs (trastuzumab plus pertuzumab and temsirolimus) were analyzed. epigallocatechin gallate 73-77 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-118 20664987-2 2010 Previous study from this laboratory has demonstrated that the combination of EGCG (25 microM) and raloxifene (4 microM) elicits a strong cytotoxic response in MDA-MB-231 human breast cancer cells, which lack the estrogen receptor (ER) and erbB-2/ Her-2 receptor. epigallocatechin gallate 77-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 239-245 19438225-6 2009 Western blotting analysis demonstrated that (-)-EGCG induced downregulation of oncogenic Hsp90 client proteins by approximately 70-95%, including Akt, Cdk4, Raf-1, Her-2, and pERK. epigallocatechin gallate 44-52 erb-b2 receptor tyrosine kinase 2 Homo sapiens 164-169 19420761-4 2009 Assays of cytoskeletal reorganization, Western blotting and immunoprecipitation suggested that EGCG inhibited this migration/invasion by suppressing the HRG-stimulated activation of epidermal growth factor receptor-related protein B2 (ErbB2)/ErbB3/protein kinase B (Akt), whereas EGC did so through pathways including the disruption of the HRG-stimulated activation of ErbB2/ErbB3 but not Akt. epigallocatechin gallate 95-99 erb-b2 receptor tyrosine kinase 2 Homo sapiens 235-240 19420761-4 2009 Assays of cytoskeletal reorganization, Western blotting and immunoprecipitation suggested that EGCG inhibited this migration/invasion by suppressing the HRG-stimulated activation of epidermal growth factor receptor-related protein B2 (ErbB2)/ErbB3/protein kinase B (Akt), whereas EGC did so through pathways including the disruption of the HRG-stimulated activation of ErbB2/ErbB3 but not Akt. epigallocatechin gallate 95-99 erb-b2 receptor tyrosine kinase 2 Homo sapiens 369-374 19189648-5 2008 RESULTS: EGCG inhibited FASN activity, induced apoptosis and caused a marked decrease of human epidermal growth factor receptor 2 (HER2), phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular (signal)-regulated kinase (ERK) 1/2 proteins, in breast cancer cells. epigallocatechin gallate 9-13 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-129 19189648-5 2008 RESULTS: EGCG inhibited FASN activity, induced apoptosis and caused a marked decrease of human epidermal growth factor receptor 2 (HER2), phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular (signal)-regulated kinase (ERK) 1/2 proteins, in breast cancer cells. epigallocatechin gallate 9-13 erb-b2 receptor tyrosine kinase 2 Homo sapiens 131-135 19325845-6 2008 EGCG inhibits the activation of EGFR (erbB1), HER2 (neu/erbB2) and also HER3 (neu/erbB3), which belong to subclass I of the RTK superfamily, in various types of human cancer cells. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 46-50 19325845-6 2008 EGCG inhibits the activation of EGFR (erbB1), HER2 (neu/erbB2) and also HER3 (neu/erbB3), which belong to subclass I of the RTK superfamily, in various types of human cancer cells. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 52-55 19325845-6 2008 EGCG inhibits the activation of EGFR (erbB1), HER2 (neu/erbB2) and also HER3 (neu/erbB3), which belong to subclass I of the RTK superfamily, in various types of human cancer cells. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 56-61 19325845-6 2008 EGCG inhibits the activation of EGFR (erbB1), HER2 (neu/erbB2) and also HER3 (neu/erbB3), which belong to subclass I of the RTK superfamily, in various types of human cancer cells. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-81 17909003-5 2007 The different modes of action of EGCG and trastuzumab led us to hypothesize that EGCG will inhibit HER2-driven breast cancer cells resistant to trastuzumab. epigallocatechin gallate 33-37 erb-b2 receptor tyrosine kinase 2 Homo sapiens 99-103 17909003-5 2007 The different modes of action of EGCG and trastuzumab led us to hypothesize that EGCG will inhibit HER2-driven breast cancer cells resistant to trastuzumab. epigallocatechin gallate 81-85 erb-b2 receptor tyrosine kinase 2 Homo sapiens 99-103 17909003-9 2007 Thus, EGCG in combination with trastuzumab may provide a novel strategy for treatment of HER2-overexpressing breast cancers, given that EGCG can cross the blood-brain barrier. epigallocatechin gallate 6-10 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-93 17909003-9 2007 Thus, EGCG in combination with trastuzumab may provide a novel strategy for treatment of HER2-overexpressing breast cancers, given that EGCG can cross the blood-brain barrier. epigallocatechin gallate 136-140 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-93 16707458-2 2006 Previously, we showed that the green tea polyphenol epigallocatechin 3-gallate (EGCG) inhibits growth of NF639 Her-2/neu-driven breast cancer cells via reducing receptor autophosphorylation and downstream Akt and NF-kappaB activities. epigallocatechin gallate 80-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 105-120 17539658-11 2007 Taken together, these findings extend our previous study to indicate that EGCG may be useful in the chemoprevention of breast carcinoma in which FAS overexpression results from HER2 or/and HER3 signaling. epigallocatechin gallate 74-78 erb-b2 receptor tyrosine kinase 2 Homo sapiens 177-181 17575143-1 2007 Previously, we showed that the bioactive green tea polyphenol epigallocatechin-3-gallate (EGCG) inhibits growth in soft agar of breast cancer cells with Her-2/neu overexpression. epigallocatechin gallate 90-94 erb-b2 receptor tyrosine kinase 2 Homo sapiens 153-162 17575143-2 2007 Using gene expression profiling, here we show that EGCG treatment of Her-2/neu-driven mammary tumor cells alters the expression of key regulators in the epithelial to mesenchymal transition (EMT) pathway, reducing invasive phenotype. epigallocatechin gallate 51-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 69-78 16416603-5 2005 Treatment of these cells with 20 microg/ml of EGCG (the IC50 concentration for growth inhibition) caused, within 6 hours, a decrease in the phosphorylated (i.e. activated) forms of not only EGFR and HER2, but also HER3. epigallocatechin gallate 46-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 199-203 16053920-2 2005 We previously reported that in the HT29 human colon cancer cell line EGCG, the major biologically active component of green tea, inhibits activation of the RTKs EGFR, HER2, and HER3, and that this is associated with inhibition of multiple downstream signaling pathways. epigallocatechin gallate 69-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 167-171 16140980-5 2005 EGCG treatment for 24 hours also caused decreased signals of HER-2/neu in esophageal adenocarcinoma OE19 cells. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 61-70 16416603-3 2005 We previously reported that in HT29 human colon cancer cells EGCG, the major biologically active component of green tea, inhibits activation of two members of this family, EGFR and HER2, and multiple downstream signaling pathways. epigallocatechin gallate 61-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 181-185 15814656-0 2005 (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. epigallocatechin gallate 0-28 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-160 15814656-1 2005 PURPOSE: (-)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. epigallocatechin gallate 9-37 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-156 15814656-1 2005 PURPOSE: (-)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. epigallocatechin gallate 9-37 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-162 15814656-1 2005 PURPOSE: (-)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. epigallocatechin gallate 39-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-156 15814656-1 2005 PURPOSE: (-)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. epigallocatechin gallate 39-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-162 15814656-6 2005 Both EGCG and Poly E caused a decrease in the phosphorylated forms of EGFR and HER2 proteins, and subsequently caused a decrease in the phosphorylated forms of the extracellular signal-regulated kinase and Akt proteins. epigallocatechin gallate 5-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 79-83 15814656-10 2005 Furthermore, when treatment was prolonged for 96 hours, 1 microg/mL of EGCG or Poly E was sufficient to inhibit growth, reduce activation of EGFR and HER2, and induce apoptosis. epigallocatechin gallate 71-75 erb-b2 receptor tyrosine kinase 2 Homo sapiens 150-154 16416603-10 2005 With a longer incubation time, 96 hours, a very low dose (1.0 microg/ml) of EGCG also caused inhibition of cell growth, inhibition of activation of EGFR, HER2, and HER3, a decrease in the levels of COX-2 and Bcl-xL proteins, and apoptosis. epigallocatechin gallate 76-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 154-158 12960141-0 2003 Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. epigallocatechin gallate 0-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 50-59 11830514-2 2002 With evidence accumulating for a chemopreventive role of green tea polyphenols, the effects of epigallocatechin-3 gallate (EGCG) on Her-2/neu-overexpressing breast cancer cells were examined. epigallocatechin gallate 95-121 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-137 11830514-2 2002 With evidence accumulating for a chemopreventive role of green tea polyphenols, the effects of epigallocatechin-3 gallate (EGCG) on Her-2/neu-overexpressing breast cancer cells were examined. epigallocatechin gallate 95-121 erb-b2 receptor tyrosine kinase 2 Homo sapiens 138-141 11830514-2 2002 With evidence accumulating for a chemopreventive role of green tea polyphenols, the effects of epigallocatechin-3 gallate (EGCG) on Her-2/neu-overexpressing breast cancer cells were examined. epigallocatechin gallate 123-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-137 11830514-3 2002 EGCG inhibited mouse mammary tumor virus (MMTV)-Her-2/neu NF639 cell growth in culture and soft agar. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-53 11830514-3 2002 EGCG inhibited mouse mammary tumor virus (MMTV)-Her-2/neu NF639 cell growth in culture and soft agar. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 54-57 11830514-4 2002 EGCG reduced signaling via the phosphatidylinositol 3- kinase, Akt kinase to NF-kappaB pathway because of inhibition of basal Her-2/neu receptor tyrosine phosphorylation. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-131 11830514-4 2002 EGCG reduced signaling via the phosphatidylinositol 3- kinase, Akt kinase to NF-kappaB pathway because of inhibition of basal Her-2/neu receptor tyrosine phosphorylation. epigallocatechin gallate 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-135